Sugarbaker D J, Flores R M, Jaklitsch M T, Richards W G, Strauss G M, Corson J M, DeCamp M M, Swanson S J, Bueno R, Lukanich J M, Baldini E H, Mentzer S J
Division of Thoracic Surgery and the Department of Pathology, Brigham and Women's Hospital, Boston, Mass 02115, USA.
J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5. doi: 10.1016/s0022-5223(99)70469-1.
Our aim was to identify prognostic variables for long-term postoperative survival in trimodality management of malignant pleural mesothelioma.
From 1980 to 1997, 183 patients underwent extrapleural pneumonectomy followed by adjuvant chemotherapy and radiotherapy.
Forty-three women and 140 men (age range 31-76 years) had a median follow-up of 13 months. The perioperative mortality rate was 3.8% (7 deaths) and the morbidity, 50%. Survival in the 176 remaining patients was 38% at 2 years and 15% at 5 years (median 19 months). Univariate analysis identified 3 prognostic variables associated with improved survival: epithelial cell type (52% 2-year survival, 21% 5-year survival, 26-month median survival; P =.0001), negative resection margins (44% at 2 years, 25% at 5 years, median 23 months; P =.02), and extrapleural nodes without metastases (42% at 2 years, 17% at 5 years, median 21 months; P =.004). Using the Cox proportional hazards, the relative risk of death was calculated for nonepithelial cell type (OR 3.0, CI 2.0-4.5; P <.0001), positive resection margins (OR 1.7, CI 1.2-2.6; P =.0082), and metastatic extrapleural nodes (OR 2.0, CI 1.3-3.2; P =.0026). Thirty-one patients with 3 positive variables had the best survival (68% 2-year survival, 46% 5-year survival, median 51 months; P =.013). A previously published staging system using these variables stratified survival (P <.05).
(1) Multimodality therapy including extrapleural pneumonectomy is feasible in selected patients with malignant pleural mesotheliomas, (2) pre-resectional evaluation of extrapleural nodes may select patients for radical therapy, (3) microscopic resection margins affect long-term survival, highlighting the need for further investigation of locoregional control, and (4) patients with epithelial, margin-negative, extrapleural node-negative resection had extended survival.
我们的目标是确定恶性胸膜间皮瘤三联疗法术后长期生存的预后变量。
1980年至1997年,183例患者接受了胸膜外全肺切除术,随后进行辅助化疗和放疗。
43名女性和140名男性(年龄范围31 - 76岁),中位随访时间为13个月。围手术期死亡率为3.8%(7例死亡),发病率为50%。其余176例患者的2年生存率为38%,5年生存率为15%(中位生存期19个月)。单因素分析确定了3个与生存率提高相关的预后变量:上皮细胞类型(2年生存率52%,5年生存率21%,中位生存期26个月;P = 0.0001)、切缘阴性(2年时为44%,5年时为25%,中位生存期23个月;P = 0.02)和无转移的胸膜外淋巴结(2年时为42%,5年时为17%,中位生存期21个月;P = 0.004)。使用Cox比例风险模型,计算了非上皮细胞类型(比值比3.0,可信区间2.0 - 4.5;P < 0.0001)、切缘阳性(比值比1.7,可信区间1.2 - 2.6;P = 0.0082)和胸膜外淋巴结转移(比值比2.0,可信区间1.3 - 3.2;P = 0.0026)的相对死亡风险。31例具有3个阳性变量的患者生存率最佳(2年生存率68%,5年生存率46%,中位生存期51个月;P = 0.013)。使用这些变量的先前发表的分期系统对生存率进行了分层(P < 0.05)。
(1)包括胸膜外全肺切除术在内的多模式治疗在选定的恶性胸膜间皮瘤患者中是可行的;(2)术前对胸膜外淋巴结的评估可筛选出适合根治性治疗的患者;(3)显微镜下切缘影响长期生存,突出了对局部区域控制进行进一步研究的必要性;(4)上皮型、切缘阴性、胸膜外淋巴结阴性切除的患者生存期延长。